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Introduction
Several well-conducted randomized controlled trials (RCTs) and systematic reviews have found that the risk of bleeding associated with long-term treatment with aspirin was lower than the risk of bleeding associated with warfarin [1, 2] . Clinical practice very frequently follows this assumption [3, 4] .
Aspirin and other antiplatelet drugs are very frequently prescribed in elderly patients for the prevention and treatment of cardiovascular diseases. Aspirin has also been considered for a long time as an alternative to anticoagulation in patients with atrial fibrillation and either low risk of embolism or contraindications for anticoagulation [5] [6] [7] . This latter situation is very common in older patients with atrial fibrillation. They receive oral anticoagulants much less frequently than they should, in most cases because their bleeding risk on anticoagulation is estimated, or perceived, to be too high [4] . Instead, those patients usually receive aspirin. Indeed, some guidelines specifically developed for older patients, as for example STOPP-START, recommend prescribing aspirin to older patients with chronic atrial fibrillation where warfarin is contraindicated [8] .
However, platelet inhibitors and oral anticoagulants have shown similar overall rates of major bleeding in several RCTs [9] [10] [11] [12] , including at least two RCTs conducted in octogenarians with atrial fibrillation [9, 13] . The latest updates of guidelines for atrial fibrillation no longer recommend the use of aspirin as a substitute for anticoagulation in this condition in the general population [6, 7] . We do not know, however, if this can be also applied to older patients. It is well known that age increases both the risk of cardiovascular events and the risk of serious bleeding [14] , but it is not clear if the risk of bleeding increases with age equally with all antithrombotic therapies.
Accurate knowledge of the comparative risk of bleeding of antiplatelet drugs and oral anticoagulants is essential for clinical decision making in many conditions requiring antithrombotic therapy in elderly patients. Therefore, we undertook a systematic review of all available controlled randomized and non-randomized studies comparing chronic treatment with any antiplatelet drug and any oral anticoagulant in patients 65 years or older and assessing hemorrhagic events.
Methods

Objective
To better define the risk of bleeding when on aspirin and other antiplatelet drugs, compared with that when on oral anticoagulants, either vitamin K antagonists or direct oral anticoagulants, in patients aged 65 years or older.
Study design
A systematic review and meta-analysis of randomized and non-randomized controlled studies.
Search strategy
We searched MEDLINE PubMed, EMBASE and the Cochrane Database of Controlled Clinical Trials, all of them from their inception to January 2016, using the following keywords:
("Aspirin In addition, we screened the reference list of included studies and of recent related reviews and guidelines. No language restriction was applied.
Criteria for including studies
We included the following.
1. Randomized controlled trials (RCTs) and, as we expected to find few true RCTs in older patients, some types of non-randomized controlled studies with a lower risk of bias: quasi-randomized controlled trials, non-randomized controlled trials, controlled before-and-after studies (where observations are prospectively made just before and after the implementation of an intervention), and prospective or retrospective parallel cohorts studies. We did not include case-control studies, historically controlled studies (patients receiving a treatment were retrospectively compared with a similar group from the past who did not), cross-sectional studies or case reports/-case series, 2. Which compared one or several antiplatelet drugs (aspirin or others) with any oral anticoagulant (warfarin, other vitamin K antagonist or any direct oral anticoagulant), 3. Included patients aged 65 years and over (70% or more of all included patients being > 65 years, or reporting separate data for this age subgroup), 4. And followed patients for at least 6 months, reporting the frequency of bleeding events.
Studies on post-or perioperative bleeding complications were excluded. Patients on combined treatment with anticoagulant and antiplatelet drugs were excluded. As our focus was the hemorrhagic risk of each treatment and not the effectiveness, we did not restrict studies by disease or by indication of the antithrombotic treatment.
Outcomes analyzed
The main outcome analyzed was major bleeding, as defined by the International Society on Thrombosis and Haemostasis (ISTH) whenever possible (any clinically overt bleeding involving a critical anatomic site or associated with death, permanent disability, a fall in hemoglobin concentration > 2 g dL À1 or requiring transfusion of ≥ 2 units of whole blood or packed red blood cells [15] ) or, if that was not possible, as defined in each study. Secondary outcomes were intracranial bleeding, anyseverity bleeding and all-cause mortality. All outcomes were analyzed at 12 months or the nearest follow-up point available.
Selection of studies for inclusion and data extraction Two authors (MM and CLL) screened all retrieved references and, based on the title and abstract, selected any study that was potentially a candidate. Two authors (all authors participated) then independently assessed every candidate study for inclusion, assessed its risk of bias and extracted data, using predefined forms. Data on age, gender, indication for antithrombotic therapy, antithrombotic drugs and doses employed, estimated risks of stroke and bleeding, main comorbidities, outcomes and funding sources were recorded. Any difference between reviewers was solved by discussion and consensus.
Statistical analysis
Data on outcomes were pooled and risk ratios calculated using the Mantel-Haenszel method and a random effect model. The presence of heterogeneity between included studies was assessed employing the Mantel-Haenszel chisquared test and the I2 statistic. If significant heterogeneity was found, we searched for an explanation based on the differences in clinical characteristics of the included studies. If the studies were found to be clinically very dissimilar they were not statistically combined.
The risk of bias of included studies was evaluated using the tool developed by the Cochrane Collaboration [16] , which assesses the risk of bias in six domains: sequence generation, allocation sequence concealment, blinding, incomplete outcome data, selective outcome reporting and 'other' potential sources of bias. In non-randomized studies we also assessed the risk of bias as a result of confounding. The possibility of publication bias was explored using a funnel plot. A post-hoc estimation of the information size (i.e. the cumulated sample sizes of all included trials) obtained by the meta-analysis for the main outcome (major bleeding) was conducted using trial sequential analysis [17] .
A sensibility analysis was carried out by selectively pooling (i) randomized controlled studies and (ii) studies including more than 500 patients.
The following subgroup analyses were predefined: (i) by age (patients between 65 and 79 years, or aged 80 years or older), (ii) by indication for anticoagulation (atrial fibrillation or other indications) and (iii) by aspirin dose (lower or greater than 100 mg day
À1
). Cochrane Review Manager was the software employed for all meta-analysis statistics (version 5.3, http://commu nity.cochrane.org/tools/review-production-tools/revman-5). Trial sequential analysis was performed using TSA software (Copenhagen Trial Unit, Rigshospitalet, Copenhagen, Denmark, http://www.ctu.dk/tsa).
Registration and reporting guidelines
This systematic review was registered in the PROSPERO international prospective register of systematic reviews with the number CRD42016035209. We followed the PRISMA statement for transparent reporting of systematic reviews (http://www.prisma-statement.org/) and produced a detailed PRISMA flowchart (Fig. 1) and checklist (available from the authors upon request). Figure 1 shows the details of the selection process. Our search yielded 1672 references, of which we selected 92 for more detailed assessment. Of these, 11 studies fulfilled the predefined inclusion criteria. Seven were RCTs [9, 12, 13, [18] [19] [20] [21] , comprising 4550 patients, and four were non-randomized cohort studies [22] [23] [24] [25] , adding another 38 649 patients. Agreement between reviewers was excellent. A funnel plot showed no evidence of publication bias.
Results
All studies but one compared aspirin or clopidogrel with warfarin. Consequently, we pooled data only for this comparison. The remaining study, the AVERROES trial, was the only one that compared aspirin against a nonvitamin-K antagonist anticoagulant, apixaban, a direct © 2017 International Society on Thrombosis and Haemostasis factor Xa inhibitor [12] . Thus, we present its results separately.
Characteristics of included studies Table 1 displays the characteristics of included studies. The mean age of included patients varied between 74 and 82 years. The main indication for antithrombotic treatment was atrial fibrillation (in all studies), associated with acute coronary disease in three studies. Five of six RCTs comparing warfarin with aspirin offered data on the time in therapeutic range. It varied between studies from 67% to 73%. None of the cohort studies provided these data.
Patients' risk of bleeding at baseline was formally assessed in only three studies and was moderate to high. The frequency of major bleeding varied largely: between 5% and 14% in most studies, it was lower (3%) in one study and higher in two (18%, 22%). These variations reflected differences in populations included and in the criteria for defining major bleeding. Major bleeding was defined following the ISTH criteria in three studies, in a manner close to the ISTH criteria in two studies, as hospitalizations related to bleeding in three studies (all three cohort studies) and, finally, using various clinical criteria in three studies ( Table 1) .
The risk of bias of included studies is shown in Fig. 2 . Overall, the quality of included RCTs was only moderate, because in most of them neither the treatment nor the assessment of hemorrhagic events was blind. The global quality of non-randomized cohort studies, in contrast, was low. They had a high risk of selection and confounding bias: baseline characteristics of patients in the different treatment groups were not entirely identical and all studies only reported crude, unadjusted incidences of bleeding. The number of patients lost during the followup was adequately described in all studies and was very low, except in the AFASAK-1 trial, in which about 20% of patients withdrew before completing the study.
Major bleeding
Six RCTs (2652 patients) and three cohort studies (11 859 analyzable patients) compared aspirin or clopidogrel and provided data on major bleeding events. Substantial heterogeneity existed between included RCTs (chisquared = 0.03; I 2 = 60%). This heterogeneity was induced by the two earliest trials, AFASAK-I and SPAF-II, which found worse results for major bleeding with warfarin, very probably explained by the fact that both trials targeted a higher INR on warfarin (2-4.5) than currently recommended (2-3). Excluding these two studies from the analysis did not change the overall results. Thus, we decided to include these two studies in the analysis but in a different subgroup. Figure 3 shows the pooled results for major bleeding comparing antiplatelet drugs and warfarin. Pooling together all included studies, randomized and non-randomized, showed a non-significant trend toward a lower risk of major bleeding with aspirin or clopidogrel, compared with warfarin (RR, 0.86; 95% confidence interval (95% CI), 0.73-1.01; P = 0.07). However, this result was not consistent and varied markedly between randomized and non-randomized studies.
No difference between antiplatelet drugs and warfarin appeared when only RCTs were analyzed, either only RCTs targeting an INR of 2-3 on warfarin (RR, 1.01; 95% CI, 0.69 to 1.48; P = 0.96) (Fig. 3) or all RCTs combined, whatever the INR targeted (RR, 0.67; 95% CI, 0.37-1.23; P = 0.20). In contrast, pooling results only from non-randomized cohort studies showed a significantly lower risk of major bleeding with antiplatelet drugs (RR, 0.87; 95% CI, 0.77-0.99; P = 0.03).
Trial sequential analysis indicated that the meta-analysis reached a large enough information size to be able to detect a relative risk difference in major bleeding equal to or greater than 14% between both comparison groups ( Figure S4) .
Finally, the only trial that compared aspirin with a nonvitamin K antagonist, apixaban, found no significant difference in the risk of major or clinically relevant non-major bleeding in the subgroup of patients > 75 years old (1898 patients; RR, 0.81; 95% CI, 0.57-1.15; P = 0.24) [12] .
Intracranial bleeding
Only three RCTs (1697 patients) and three cohort studies (24 059 analyzable patients) reported data on intracranial bleeding. Results followed a similar pattern to that for major bleeding, as shown in Fig. 4 : no significant difference appeared within RCTs (RR 0.61, 95% CI 0.28-1.32, P = 0.21), whereas the risk of intracranial bleeding appeared to be significantly lower with aspirin or clopidogrel in non-randomized studies (RR, 0.41; 95% CI, 0.24-0.70; P = 0.001). No significant heterogeneity was present for this outcome.
Any-severity bleeding
Five RCTs (1882 patients) and two cohorts studies (21 605 patients) compared aspirin or clopidogrel with warfarin and reported bleeding of any severity. Results are displayed in Fig. 5 . The risk of any bleeding was significantly lower with aspirin or clopidogrel compared with warfarin (RR, 0.70; 95% CI, 0.57 to 0.86; P = 0.0008). Results from RCTs and cohort studies were coincident for this outcome.
Mortality
Four RCTs (2214 patients) and only one cohort study (5 617 analyzable patients) compared aspirin with warfarin and assessed all-cause mortality. Results are shown in Fig. 6 . No difference appeared in all-cause mortality between aspirin and warfarin (RR, 0.99; 95% CI, 0.82-1.21; P = 0.96). Results from RCTs and non-randomized studies were coincident. Significant heterogeneity existed: (i) between RCTS, induced once again by the AFASAK-I trial, and (ii) in the various cohorts of the study by Fosbol et al. Excluding these two studies from the analysis did not change the results.
Subgroup and sensitivity analysis
The risk of major hemorrhage appeared to be significantly higher with warfarin when only studies where the mean age of included patients was 80 years or older were pooled (RR, 0.80; 95% CI, 0.69-0.90; P = 0.93, P = 0.004). Conversely, when only studies with a mean patient age of 65-80 years were analyzed, this risk was not significantly different (RR, 0.87; 95% CI, 0.64-1.19) ( Figure S1 ). The two age subgroups were not, however, significantly different (P = 0.62). The risk of major bleeding did not change when studies using doses of aspirin lower or greater than 100 mg day
À1
were analyzed separately ( Figure S2 ). There was no significant difference in either case.
Two non-randomized cohort studies compared warfarin with dual antiplatelet therapy (aspirin plus clopidogrel) [23, 24] . Pooling these two studies separately (post-hoc analysis) showed no significant difference in major bleeding between dual antiplatelet therapy and warfarin (RR, 0.90; 95% CI, 0.75-1.09). Pooling only the studies comparing warfarin with single antiplatelet therapy did not change the main results ( Figure S3 ).
Regarding sensitivity analysis: (i) differences in results between RCTs and non-randomized studies existed for major and intracranial bleeding and have already been described; (ii) pooling only the studies that included more than 500 patients did not modify the overall results.
Discussion
We conducted a thorough search and analysis of available evidence comparing the risk of bleeding when on antiplatelet or oral anticoagulant drugs in patients older than 65 years. We found that, in this population, the risk of major hemorrhage associated with chronic treatment with antiplatelet drugs is very close to the risk associated with oral anticoagulants. Much closer than many clinicians assume in daily practice.
Overall, our results show that bleeding of any severity is less frequent with aspirin than with warfarin (a 30% relative risk reduction) but that this difference is mostly because of minor bleeding events. Major bleeding when on aspirin or clopidogrel was either as frequent as when on warfarin (in RCTs targeting an INR between 2 and 3) or significantly less frequent than with warfarin (in nonrandomized cohort studies) but just by a modest 14% relative reduction. That would translate, taking into account a frequency of major bleeding with warfarin of 5-14% as observed in the studies included in this review, into an absolute reduction of just one to two major bleeding events per 100 patients per year.
The design and methods of the studies influenced the results obtained on major and intracranial bleeding. Early RCTs comparing warfarin and aspirin employed greater doses of warfarin and targeted higher INRs. It is not then surprising that they found a significantly higher risk of major bleeding with warfarin. However, these first results have conditioned for a long time our understanding of the hemorrhagic risk associated with aspirin and warfarin in older patients. If asked, most clinicians would consider the risk of major bleeding in older patients as being noticeably lower with aspirin than with warfarin.
Evidence from more recent RCTs, which targeted INRs of 2-3, gives us, however, a very different estimate. These studies found no difference between aspirin and warfarin concerning the risk of major hemorrhage in older patients, not even a trend, either in each trial individually or in their meta-analysis. Another large RCT [12] compared aspirin with apixaban, a non-vitamin-K oral anticoagulant, and also found no difference in major bleeding between aspirin and anticoagulation in older patients.
Finally, in non-randomized parallel cohort studies, the risk of major and intracranial bleeding seemed to be significantly lower with aspirin or clopidogrel, compared with warfarin. It is very important to note, however, that the risk of bias of these non-randomized studies is high and the quality of the evidence they provide is clearly lower than that of RCTs. Very probably, patients in the various treatment groups were not entirely comparable in these cohort studies. It is also likely that control of anticoagulation with warfarin was of poorer quality in those studies than in RCTs and that hemorrhagic events were not reported equally for all treatment groups. On the other hand, cohort studies included a larger number of patients than RCTs and the estimates they provide might be closer to everyday practice in real life.
Subgroup analysis suggests that, if any significant difference in major bleeding does actually exist, this difference would happen especially in the oldest patients, those aged over 80 years. Besides, analysis of secondary outcomes showed a lower risk of intracranial hemorrhage when on antiplatelet drugs. Nonetheless, caution is needed in interpreting these findings. Results for patients older than 80 years are largely determined by the weight of non-randomized studies and this subgroup was not statistically significantly different from the 65-80 years subgroup. Results for intracranial bleeding seem to be more consistent, but if we take into account only RCTs, the best evidence, they are not significant.
Previous systematic reviews and meta-analyses on this subject had reached inconsistent results. Warkentin et al. [26] conducted recently a systematic review very similar to ours, except that they included only RCTs. They also found no significant difference in major hemorrhage between aspirin and warfarin, even if minor bleeding was significantly more frequent with warfarin. Hart et al. also found in their meta-analysis significantly fewer intracranial hemorrhages with aspirin but no significant difference in the risk of major extracranial hemorrhage [27] . Two other systematic reviews found significantly less major bleeding when on aspirin than when on warfarin [1, 2] . All these reviews included patients of all ages and Test for overall effect: Z = 3.37 (P = 0.0008) Test for subgroup differences: Chi 2 = 0.67, df = 1 (P = 0.41), I 2 = 0% did not study specifically elderly patients, as we have done.
The main limitation of our systematic review is probably the heterogeneity observed: patients, definition and reporting of major bleeding, study design and risk of bias differed, more or less, between included studies. This heterogeneity undoubtedly contributes to the inconsistency of results between RCTs and non-randomized studies and may reduce our confidence in the global pooled results. However, heterogeneity was not present everywhere. It was mainly because of two sets of studies: (i) older RCTs with a higher INR target and (ii) cohort studies, which differ substantially with RCTs and between themselves. By contrast, RCTs targeting an INR of 2-3 show no heterogeneity and are very consistent in their results. Another possible limitation of this review is that patients included in those studies were generally not very ill, so we do not know whether these results could be extrapolated to sicker patients or to the very old. Finally, this work could be criticized because it did not assess the concomitant risk of stroke and cardiovascular events in the same patients. However, that was beyond the scope of our study, which was focused on the hemorrhagic risk, and other systematic reviews and meta-analyses have already extensively studied this aspect [1, 2, [5] [6] [7] 27] .
In conclusion, the risk of any-severity bleeding in elderly patients appears to be significantly higher with warfarin than with antiplatelet agents. However, concerning the risk of major bleeding, there is actually no evidence in randomized clinical trials of any difference between either aspirin or clopidogrel and warfarin (using a target INR 2 to 3) or apixaban. Large cohort studies suggest that in real-life conditions, and assuming a probable selection bias, there are fewer major bleedings with long-term aspirin or clopidogrel than with warfarin, but that this difference is small.
These results mean that patients older than 65 years who are at high risk of major bleeding on warfarin are also at high risk of major bleeding on antiplatelet drugs, even at a low dose. Thus, the indication for a treatment with antiplatelet drugs in these patients should be carefully weighed against the risk. Antiplatelet drugs should not be employed in any case as an alternative to anticoagulation in older patients, as they carry a risk of major bleeding that appears to be equal or very close to that of oral anticoagulants. More research is needed to improve our ability to estimate the hemorrhagic risk of elderly patients on different antithrombotic treatments.
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